Health Condition 1: C419- Malignant neoplasm of bone and articular cartilage, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Intervention2: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: Histologically confirmed diagnosis of osteosarcoma Age more than and equal to 15 years Extremity location Treatment naïve
Exclusion criteria
Exclusion criteria: Prior inadvertent treatment Non-osteosarcoma histology Non-extremity osteosarcomas
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the survival following treatment with surgery and OGS-12 chemotherapy protocol in newly diagnosed, treatment naïve, extremity osteosarcoma patients. The following survival endpoints will be considered: event-free survival (DFS, as the primary endpoint), and overall survival (OS, as the secondary endpoint). To evaluate fertility outcomes, long-term complications, and occupational rehabilitation among treated patients according to the following: 1. Age at menarche 2. Resumption of menarche 3. Semen/oocyte cryopreservation 4. Marriage 5. Live births 6. Long-term complications 7. Schooling 8. Jobs Timepoint: from 01/01/2017 to 31/01/2021 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To evaluate the prognostic impact (in terms of EFS, OS) according to: a.Histological response b.Baseline nutritional parameters (hemoglobin, serum alkaline phosphatase, albumin) c.Treatment duration 2) To evaluate toxicities associated with OGS-12 chemotherapy protocol 3) To evaluate treatment compliance a.Incidence of treatment abandonment b.Reason for treatment abandonment c.Time from 1st chemotherapy cycle to 8th chemotherapy cycle (dose intensity)Timepoint: from 01/01/2017 to 31/01/2021 | — |
Countries
India
Contacts
Public ContactDr. Laboni Sarkar
Tata Memorial Centre Mumbai
Outcome results
None listed